Reactive arthritis following BCG immunotherapy for bladder carcinoma.
Intravesical instillation of bacillus Calmette-Guérin (BCG) is used in the treatment of patients with intermediate and high-risk superficial bladder carcinoma with efficacy and safety. The vast majority of patients do not present any side effects and only 5% of patients have mild and short-lived clinical manifestations such as malaise, low-grade fever, cystitis, and hematuria. Arthralgia and/or arthritis is one of the rare severe complications following intravesical BCG immunotherapy. We report here the case of a patient with reactive arthritis successfully treated with nonsteroidal anti-inflammatory drugs (NSAIDs) after the discontinuation of BCG immunotherapy.
Tinazzi
Elisa
E
Department of Clinical and Experimental Medicine, Section of Internal Medicine, University of Verona, Policlinico G.B. Rossi, Italy.
Ficarra
Vincenzo
V
Simeoni
Sara
S
Peterlana
Dimitri
D
Lunardi
Claudio
C
D000283:Administration, Intravesical; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016918:Arthritis, Reactive / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D001500:BCG Vaccine / Q000009:adverse effects* / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects; D008297:Male; D009367:Neoplasm Staging; D018570:Risk Assessment; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001500:BCG Vaccine